Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Galapagos NV ADR (GLPG)

Galapagos NV ADR (GLPG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,075,191
  • Shares Outstanding, K 65,900
  • Annual Sales, $ 298,280 K
  • Annual Income, $ 80,160 K
  • EBIT $ -203 M
  • EBITDA $ -154 M
  • 60-Month Beta 0.18
  • Price/Sales 6.24
  • Price/Cash Flow 43.51
  • Price/Book 0.66

Options Overview Details

View History
  • Implied Volatility 78.71% (-15.09%)
  • Historical Volatility 24.32%
  • IV Percentile 82%
  • IV Rank 49.17%
  • IV High 132.05% on 11/10/25
  • IV Low 27.11% on 08/18/25
  • Expected Move (DTE 10) 0.51 (1.61%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 4
  • Volume Avg (30-Day) 4
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 607
  • Open Int (30-Day) 1,093
  • Expected Range 31.12 to 32.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate 0.01
  • Low Estimate -0.41
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.13 +4.98%
on 11/20/25
33.12 -4.50%
on 11/12/25
+0.10 (+0.32%)
since 11/07/25
3-Month
29.81 +6.11%
on 11/05/25
37.78 -16.28%
on 10/03/25
-1.04 (-3.18%)
since 09/09/25
52-Week
22.36 +41.46%
on 02/10/25
37.78 -16.28%
on 10/03/25
+4.85 (+18.11%)
since 12/09/24

Most Recent Stories

More News
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Pharvaris (PHVS) and Stevanato Group (STVN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Galapagos (GLPG – Research Report), Pharvaris (PHVS – Research Report) and Stevanato Group (STVN –...

PHVS : 24.04 (-5.17%)
GLPG : 31.63 (+0.44%)
STVN : 21.29 (-0.88%)
Kepler Capital Remains a Sell on Galapagos (0JXZ)

Kepler Capital analyst Christophe dombu maintained a Sell rating on Galapagos on October 2 and set a price target of €23.50. The company’s shares closed last Thursday at €30.50.Elevate Your Investing...

GLPG : 31.63 (+0.44%)
Galapagos Updates on Cell Therapy Business Strategic Review

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

GLPG : 31.63 (+0.44%)
Galapagos Announces CFO Exit With No Successor Named Yet: Retail’s Disappointed

The company expects to announce a new CFO “in the coming months.”

SBIO : 50.53 (-2.11%)
SPDW : 44.09 (-0.07%)
GLPG : 31.63 (+0.44%)
Galapagos Stock Surges On Strategic Spin-Off And Restructuring Plans: Retail Turns Extremely Bullish

The Belgium-based biotech company said it would reduce its workforce by 40%, eliminating about 300 positions across Europe.

GILD : 119.36 (-1.51%)
GLPG : 31.63 (+0.44%)
+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients

/PRNewswire/ -- The Lausanne-based team of US investment firm, +ND Capital, today marked its second successful exit in the European biotechnology market as...

GLPG : 31.63 (+0.44%)
Why Galapagos Trounced the Market Today

A high-profile healthcare industry executive has been tapped as the company's new CEO.

GLPG : 31.63 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include...

See More

Key Turning Points

3rd Resistance Point 32.23
2nd Resistance Point 32.02
1st Resistance Point 31.82
Last Price 31.63
1st Support Level 31.42
2nd Support Level 31.21
3rd Support Level 31.02

See More

52-Week High 37.78
Fibonacci 61.8% 31.89
Last Price 31.63
Fibonacci 50% 30.07
Fibonacci 38.2% 28.25
52-Week Low 22.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar